MCT-275

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameMCT-275

Drug Alias NameIg-peptide (MultiCell Technologies)type 1 diabetes therapy (MultiCell Technologies)MCT-275

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Recombinant polypeptide

Mechanisms of ActionT lymphocytes inhibitors

TargetsUpdating

Therapy Area/IndicationsDiabetes Mellitus, Type 1

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesMulticell Technologies

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMulticell Technologies

Active IndicationsN/A

Inactive IndicationsDiabetes Mellitus, Type 1

Other Information

ATC CodeN/A